Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 20170712103633
Coronary artery disease (CAD) is the leading cause of death worldwide
and is expected to remain so for the foreseeable future due to both the
ageing population and the increasing prevalence of risk factors such as
hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk
factor in the development of heart failure (HF). At the 2nd Asia Pacific
CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of
international and regional experts discussed current strategies for
managing stable CAD and HF and highlighted areas where patient outcomes
may be improved.
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.